To the editor

Annals of Internal Medicine

Volumn 163, Issue 3, 2015, Pages 241-

  Liakos, Aris ^a   Athanasiadou, Eleni ^a   Mainou, Maria ^a   Bekiari, Eleni ^a   Haidich, Anna Bettina ^a   Rizos, Evangelos C ^b   Tsapas, Apostolos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; SERINE PROTEINASE;

ADULT; ALL CAUSE MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DECISION MAKING; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; LETTER; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIMULATION; SYSTEMATIC REVIEW (TOPIC); THEORY; UNSTABLE ANGINA PECTORIS; FEMALE; IMMUNOLOGY; MALE;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84938807610     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/L155118     Document Type: Letter

References (4)

1. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia. A systematic review and meta-analysis. Ann Intern Med. 2015;163:40-51. [PMID: 25915661] doi:10.7326/M14-2957
2. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351-75. [PMID: 15116347]
3. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. 2007;147: 578-81. [PMID: 17679700]
4. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-99. [PMID: 25773378] doi:10.1056/NEJMoa1501031